Cresols
EMOLECULES INC 5467-74-3 | (4-Bromophenyl)boronic acid | ChemScene | MFCD00002104 | 200.830 | C6H6BBrO2 | 98.000 | OB(O)c1ccc(Br)cc1 | 100g | 536853479
(4-Bromophenyl)boronic acid | ChemScene | 5467-74-3 | MFCD00002104 | 200.830 | C6H6BBrO2 | 98.000 | OB(O)c1ccc(Br)cc1 | 100g | 536853479
![MEDCHEMEXPRESS LLC L-lysine, N6-[4-(4-iodophenyl)-1-oxobutyl]-, 1,1-dimethylethyl ester | 2703051-80-1 | 98.1% | 474.38 | C20H31IN2O3 | 10 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000288028.png-250.jpg)
MEDCHEMEXPRESS LLC L-lysine, N6-[4-(4-iodophenyl)-1-oxobutyl]-, 1,1-dimethylethyl ester | 2703051-80-1 | 98.1% | 474.38 | C20H31IN2O3 | 10 MG
A lysine-based pharmacokinetic (PK) modifier supplied as a small-mass tert-butyl ester for use in the synthesis of PSMA-targeting ligands. It is designed to improve pharmacokinetic properties such as plasma residence time and to reduce off-target uptake, making it useful for targeted imaging and radionuclide therapy research.
- Improves plasma residence time by enhancing albumin binding.
- Reduces salivary gland uptake to help minimize off-target accumulation.
- Suitable for incorporation into PSMA-targeting ligand synthesis workflows.
- High purity appropriate for research use (98.1%).
- Supplied as a tert-butyl ester for convenient synthetic handling.
MEDCHEMEXPRESS LLC Moracin p | 102841-46-3 | 99.6% | 326.34 | C19H18O5 | 10 MG
Moracin P is a 2-arylbenzofuran isolated from Mori Cortex Radicis. It inhibits hypoxia-inducible factor (HIF-1), reduces oxygen-glucose deprivation (OGD)-induced reactive oxygen species (ROS), and demonstrates neuroprotective and anti-inflammatory effects - suitable for in vitro and in vivo research applications.
- Demonstrates HIF-1 inhibitory activity.
- Reduces ROS production in OGD models.
- Exhibits neuroprotective effects.
- Shows anti-inflammatory activity.
- High purity (≈99.6%) and solid form; highly soluble in DMSO (≥100 mg/mL).
- Stability: store protected from light at 4°C; in solution store at -80°C (6 months) or -20°C (1 month).
MEDCHEMEXPRESS LLC JIB-04 | 199596-05-9 | 98.3% | 308.76 | 1 ML
JIB-04 is a pan-selective Jumonji histone demethylase inhibitor. It exhibits IC50s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively. It is intended for research use only.
- Is consistently selective for cancer versus normal cells.
- Inhibits cellular Jumonji demethylase activity.
- Significantly inhibits the proliferation of glioblastoma cell lines.
- Exerts maximal inhibitory activity against KDM5A.
- Modulates the expression of genes involved in cancer cell growth.
- Leads to hypermethylation of H3K4.
- Activates autophagy and apoptotic pathways.
- Inactivates PI3K.
- Cooperates with temozolomide in killing glioblastoma cells.
- Results in a significant reduction in cancer-induced death rates in mice, prolonging survival.
MEDCHEMEXPRESS LLC P 22077 | 1247819-59-5 | 98.42% | 315.32 | 100 MG
P 22077 is a cell-permeable ubiquitin-specific protease 7 (USP7) inhibitor, also inhibiting USP47. It causes DUBs inhibition in HEK293T cells and significantly reduces the viability of Neuroblastoma (NB) cells. P 22077 increases p53 activity, inducing apoptosis in p53 wild-type and HDM2-expressing NB cells, and enhances the cytotoxic effects of Dox and VP-16. In vivo, it exhibits potent antitumor activities in xenograft mouse models.
- Cell-permeable ubiquitin-specific protease 7 (USP7) inhibitor
- Also inhibits USP47
- Reduces neuroblastoma cell viability
- Increases p53 activity and induces apoptosis
- Enhances Dox and VP-16 cytotoxic effects
- Demonstrates potent antitumor activities in mouse models
MEDCHEMEXPRESS LLC M-PEG-mal (MW 30000) | 98.0% | 500 MG
M-PEG-mal (MW 30000) is a PEG-based PROTAC linker utilized in the synthesis of PROTACs. PROTACs consist of two distinct ligands joined by a linker; one ligand targets an E3 ubiquitin ligase, and the other targets a specific protein. These molecules leverage the intracellular ubiquitin-proteasome system for selective degradation of target proteins.
- PEG-based PROTAC linker
- Enables synthesis of PROTACs
- Utilizes the ubiquitin-proteasome system
- Degrades target proteins selectively
- Features two ligands connected by a linker
- One ligand for E3 ubiquitin ligase, one for target protein
MEDCHEMEXPRESS LLC M-PEG17-acid | 2346581-96-0 | 98.5% | C36H72O19 | 100 MG
m-PEG17-acid is a PEG-based PROTAC linker utilized in the synthesis of PROTACs. These molecules employ the intracellular ubiquitin-proteasome system for the selective degradation of target proteins.
- PEG-based PROTAC linker.
- Used in the synthesis of PROTACs.
- Facilitates selective degradation of target proteins via the ubiquitin-proteasome system.